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Abstract
Background: To investigate whether expression of carbonic anhydrase XII (CA12) is associated with histologic
grade of the tumors and radiotherapy outcomes of the patients with invasive cervical cancer.
Methods: CA12 expression was examined by immunohistochemical stains in cervical cancer tissues from 183
radiotherapy patients. Histological grading was classified as well (WD), moderately (MD) or poorly differentiated (PD).
Oligonucleotide microarray experiment was performed using seven cervical cancer samples to examine differentially
expressed genes between WD and PD cervical cancers. The association between CA12 and histological grade was
analyzed by chi-square test. CA12 and histological grades were analyzed individually and as combined CA12 and
histologic grade categories for effects on survival outcome.
Results: Immunohistochemical expression of CA12 was highly associated with the histologic grade of cervical
cancer. Lack of CA12 expression was associated with PD histology, with an odds ratio of 3.9 (P = 0.01). Microarray
analysis showed a fourfold reduction in CA12 gene expression in PD tumors. CA12 expression was marginally
associated with superior disease-free survival. Application of the new combined categories resulted in further
discrimination of the prognosis of patients with moderate and poorly differentiated tumor grade.
Conclusions: Our study indicates that CA12 may be used as a novel prognostic marker in combination with
histologic grade of the tumors.
Background
CA12 is one of the tumor-associated antigens known to be
overexpressed under hypoxic conditions. Overexpression
of CA12 is also observed in von Hippel-Lindau(VHL)-
defective tumor cells with CA9, and is believed to contri-
bute in an acid extracellular PH in malignant tumors [1,2].
However, in our previous study, CA12 was highly
expressed (70%-100%) in normal cervical tissues and cervi-
cal intraepithelial neoplasia (CIN), whereas CA12 expres-
sion was lower in invasive cervical cancer (40%) [3]. We
also found that CA12 is expressed more highly in CIN I
and II than in CIN III (100% in CIN I and II and 70% in
CIN III). High expression of CA12 mRNA was associated
with significantly superior survival in another group of
cervical cancer patients [4]. Our observation can be sup-
ported with the work of Wykoff et al., who showed that
CA12 is highly expressed in the in situ lesions than in
invasive lesions in breast cancer [5].
Histological grading of differentiation for solid tumors
i sg e n e r a l l yc o n s i d e r e dt ob eo n eo ft h em o s ti m p o r t a n t
prognostic factors. The conventional histological grading
of epithelial carcinoma is determined by the microscopic
features which represent the extent of similarity of tumor
cells to normal cells. These features include mitotic activ-
ity, nuclear pleomorphism, and nucleo-cytoplasmic ratio
of the cancer cells. However, histological grading is fre-
quently open to considerable subjectivity among the
observers [6-8] and it is commonly known that only
about 20%-30% of examined specimens are clearly classi-
fied as WD or PD, with the majority tumors being left in
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passes tumors with varying clinical behaviour.
Based on this background, we hypothesized that
examination of CA12 expression might be a useful clini-
cal tool in discriminating the prognosis of cervical can-
cer with the same histological grading. To test this
hypothesis, we examined the immunohistochemical
expression of CA12 in 183 invasive cervical cancers and
investigated its possible correlation with conventional
histologic differentiation. The prognostic value of CA12
and histological grading of the tumors was analyzed
individually and then as a new combined parameter to
determine whether the combined parameter might be
clinically useful in further individualized prediction of
the prognosis of cervical cancer.
Methods
Patients and treatment
A total of 183 consecutive patients treated with radio-
therapy and/or chemotherapy were included in this
study. The study was performed with the approval of
our Institutional Review Board, and informed consent
was obtained from all patients to collect and use the
tumor samples. CA12 expression and histological differ-
entiation were determined for the cervical cancer sam-
ples by one pathologist. The patients were treated
primarily by radiotherapy with or without chemotherapy
between July 2003 and December 2006 at the National
Cancer Center, Korea. The clinical stage was determined
using the International Federation of Gynecology and
Obstetrics (FIGO) criteria and the staging work-up
included a bimanual physical examination, simple chest
radiography, cystoscopy and rectosigmoidoscopy in all
patients. Nodal status was determined by magnetic reso-
nance imaging of the pelvis ± positron emission tomo-
graphy except for the 36 patients who also undertook
laparoscopic lymph node staging as a part of our pre-
vious clinical trial.
Radiotherapy consisted of whole-pelvic external-
beam radiotherapy (EBRT) and high-dose-rate (HDR)
brachytherapy. A midline block (MLB) was inserted at
36-45 Gy, and the rest of the pelvis was treated with
up to 45-50.4 Gy. HDR brachytherapy was performed
at the beginning of MLB with fractional doses of 4-5
Gy, as 5-7 fractions twice a week. Most patients
received concomitant weekly cisplatin (40 mg/m
2)d u r -
ing EBRT, except for 26 elderly patients with expected
poor compliance. Ten patients with stage IVB cervical
cancer received 5-FU/cisplatin chemotherapy. The
median follow-up period was 25 months (range, 2-50)
at the time of the current analysis. The median follow-
up of the patients without recurrent events was
26 months (range, 2-50).
Histologic grade and immunohistochemical expression of
CA12 in cervical cancer
Tissue samples were composed of 2~4 pieces measuring
approximately 3 × 3 mm each obtained by multiple
punch biopsies. All pieces of tumors were formalin-fixed
and paraffin-embedded into a single block. Hematoxy-
lin-Eosin stained slides were prepared for determination
of histologic grading. Squamous cell carcinoma was
graded by modified Broder’s method [9], which is cur-
rently the most widely used histologic grading system.
Adenocarcinoma was graded by conventional methods,
based on the architectural and nuclear features [10].
Immunostaining for CA12 was performed by using the
avidin-biotin peroxidase complex method which was
described previously [3]. Briefly, the samples were incu-
bated with a 1:1600 dilution polyclonal antibody against
human recombinant CA12 (a gift from Dr. W. Sly,
Department of Biochemistry, Saint Louis University,
Saint Louis, MO, USA) after dewaxing. For antigen
retrieval of CA12, the slides were boiled in retrieval
solution (DAKO Corporation, Carpinteria, CA) at 98°C
for 15 minutes. Tumor cells were counted in five differ-
ent high-power fields and percentage of positive tumor
cells was calculated, taking into account the number of
tumor cells across the tissues examined. CA12 expres-
sion was scored as positive (≥ 5%) or negative (< 5%).
Oligonucleotide microarray experiment and data analysis
Twenty-four frozen tissue samples were analyzed by oli-
gonucleotide microarray as part of another study that
was not published. Of these, seven cancer tissues with
WD and PD histologic grade were analyzed to compare
gene expression pattern between the WD vs. PD tumors.
These seven samples were composed of 5 PD and 2 WD
SCC; all 7 tumors were obtained from the patients who
were also included in the current immunohistochemical
study.
Statistical analysis of the CA12 expression, histologic
grade, and radiotherapy outcomes
The primary endpoints for radiotherapy outcome were
D F Sa n dL R F S .L R F Sa n dD F Sw e r ec a l c u l a t e da st h e
date from the start of radiotherapy to local relapse and
relapse in any site, respectively. Local recurrence
included the recurrent diseases at the cervix and para-
metrial tissues. Persistent local diseases at 3 months
after completion of radiotherapy were considered as
local relapses. Patients were censored at the time of
death and also at their last follow-up visit. The chi-
squared tests were used to examine associations
between CA12 protein expression and each of other
categorical variables. Analyses for association with survi-
val outcomes were performed using the Cox regression
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were analyzed separately for their association with survi-
val outcomes. Then, histologic grade and CA12 expres-
sion were individually scored to be combined into three
categories. Scores were generated as follows: score for
CA12 expression; 1: negative CA12 expression (CA12
(-)), 2: positive CA12 expression (CA12 (+)); score for
histologic grade 1: PD, 2: MD, 3: WD. These two differ-
ent scores were added up to generate three combined
categories: category1 (score ≥ 4): CA12 (-)/WD, CA12
(+)/WD, and CA12 (+)/MD; category2 (score = 3):
CA12 (+)/PD, CA12 (-)/MD; category3 (score = 2):
CA12 (-)/PD.
Association between combined categories and survival
outcomes was examined in all patients except for the 10
patients who had missing values either in histologic
grade or in CA12. Both univariate and multivariate ana-
lyses were performed using the Cox regression model.
The category1 was considered as the reference group
for estimation of hazard ratio (HR). Survival distribu-
tions according to CA12 expression, histologic grade,
and combined categories of both variables were gener-
ated using the Kaplan-Meier method and the log-rank
test was used for comparing the survival distribution.
The validity of associations between CA12 expression
and histologic grade was examined in the patients of
WD and PD tumors using the logistic regression. Statis-
tical significance was defined as p < 0.05. All statistical
analyses were performed using the STATA statistical
software, Version 10 (STATA, College Station, TX).
Results
Radiotherapy Outcome
From the start of the study period until the time of ana-
lysis, 55 patients had disease progression, including 21
local recurrences, 1 regional recurrence, and 40 distant
metastases. Seven patients developed both local and dis-
tant recurrences. The patients were followed up for a
median period of 29 months (range, 5 to 56 months)
and the median follow-up for the patients without
recurrence was 32 months (range, 6 to 58 months).
CA12 expression and clinicopathological characteristics of
cervical cancer
Immunohistochemical staining for CA12 showed a pro-
minent membranous pattern in individual tumor cells.
Cytoplasmic staining was occasionally noted, but nuclear
staining was not observed. Typical examples of CA12
expression are shown in Figure 1. The clinicopathologi-
cal characteristics and their association with CA12
expression are shown in Table 1. Younger age (≤ 40),
more differentiated histology, and SCC histological type
were all significantly associated with positive CA12
expression (P < 0.05). The other parameters had no sig-
nificant association with CA12 expression.
CA12 expression is associated with histological
differentiation of cervical cancer
CA12 expression was observed in 57.1% (16/28), 48.3%
(56/116), and 25.0% (9/36) of WD, MD, and PD tumors
respectively, with differences that were statistically sig-
nificant (c
2 test, P = 0.02; Table 1). Logistic regression
analysis was performed for further examination of the
CA12 expression to discriminate between the two
extreme grades of histological differentiation. Tumors
negative for CA12 expression were 3.9 times more likely
to be poorly differentiated than were CA12-positive
tumors (P = 0.01).
Regarding the microarray analysis, average linkage
hierarchical clustering of the seven samples showed that
WD and PD tumors tended to be located more closely
in each subset (Figure 2(A)). Microarray analysis showed
that CA12 was one of the most significantly down-regu-
lated genes out of all the down-regulated genes in
tumors with PD histology. Four-fold reduction in CA12
gene expression was observed compared with expression
in tumors with WD histology. Real-time polymerase
chain reaction of the CA12 gene, normalized to the con-
t r o lg e n e ,r e v e a l e da ne v e nl a r g e rd i f f e r e n c ei ni t s
expression between WD and PD tumors, with mean
CA12/b-actin ratios of 13-15 and 0.1-1.0, respectively
(Figure 2(B)). This result was in concordance with the
results from the immunohistochemical stains.
Biological data mining showed that genes associated
with the immune response (T cell receptor alpha, beta,
gamma loci), major histocompatibility complex (MHC)
class II receptor activity (HLA-DQB1, DPA1, DRB4,
DOA, DPA1), and organismal physiological processes in
calcium homeostasis, carbohydrate and lipid metabolism
were up-regulated in PD tumors, whereas those related
to ectoderm development, organogenesis, the intermedi-
ate filament cytoskeleton and the plasma membrane,
and carbonic anhydrase activity were down-regulated.
The latter two functions were also annotated for cellular
structure and molecular functions which relate to CA12
in gene ontology analysis.
CA12, histological grade, and survival outcomes
Positive CA12 expression was marginally associated with
superior DFS in uni-and multivariate analysis (Figure 3(A),
Table 2) compared to the negative one. Positive CA12
expression showed a tendency for superior DFS (P = 0.06;
Figure 3A) and was associated with superior LRFS (P =
0.05; Figure 3B) by the log rank test. Histologic grade was
a significant factor in influencing DFS and LRFS (Figure 4
(A)(B)). Although no statistically significant differences
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respect to DFS and LRFS, the difference between the WD
and PD tumors was significant (Table 2, 3). DFS and LRFS
w e r es i g n i f i c a n t l yi n f e r i o ri nP Dt u m o r st h a ni nM D
tumors (Hazard ratio 2.22, 95% confidence interval 1.23-
3.98, p = 0.008 for DFS, Hazard ratio 3.85, 95% confidence
interval 1.60-9.24, p = 0.003 for LRFS). In the multivariate
analyses, worse DFS was also influenced by younger age,
adenocarcinoma histology, large tumor size, and advanced
FIGO stages (Table 2). Other parameters associated with
worse LRFS were adenocarcinoma histology, large tumor
size, and advanced FIGO stages (Table 3).
The new combined category of CA12 expression and
histological grade is significantly associated with survival
outcomes
Since CA12 and histological grade individually showed a
significant correlation with survival outcomes, we gener-
ated a new score in order to examine whether the com-
bined category of the two factors would improve the
discriminatory power of histologic grade on the survival
outcomes or not. Patients with MD or PD tumors were
divided into category 1 or 2, and 2 or 3, based on CA12
expression, respectively. There were significant differ-
ences in both DFS and LRFS among the three combined
categories (Figure 5). Multivariate analyses using the
Cox regression showed that, the DFS and LRFS for the
patients with MD and PD tumors were further divided
by CA12 expression (Table 4).
Discussion
I no u rs t u d y ,w ed i s c o v e r e dt h a tC A 1 2e x p r e s s i o nw a s
strongly associated with histologic grades of the cervical
cancer. As CA12 and histologic grade were significantly
associated with each other, we then examined whether
an application of combined categories of CA12 and his-
tological grade could be used to improve the discrimina-
tion power for patient survival. We were particularly
interested to find out if we might be able to break down
the patient group of MD into better or worse prognostic
group under the basis of CA12 expression. However,
when CA12 expression was introduced into the conven-
tional histologic grading system, both the prognosis of
MD and PD tumors were shown to be influenced by
CA12 expression. The prognosis of MD tumors with
Figure 1 Expression of CA12 in uterine cervical cancer. (A) Negative for CA12, (B) 5%, (C) 70% positive for CA12. CA12 protein was expressed
at the cell membrane (Original magnification × 200).
Table 1 Expression of CA12 in cervical cancer: correlation
with clinicopathological characteristics
Total No CA12 expression P*
Negative Positive
Age
≤ 40 years 30 11 19 0.02
>40 years 153 91 62
Histology
SCC 167 89 78 0.03
AD 16 13 3
Differentiation
WD 28 12 16 0.02
MD 110 57 53
PD 35 27 8
Size of tumor
≤ 4c m 7 6 4 6 3 0 0.31
> 4 cm 107 56 51
Nodal status
Positive 105 61 44 0.46
Negative 78 41 37
FIGO stage
I~IIB 139 80 59 0.68
IIIA~IVA 32 16 16
IVB 12 6 6
Smoking
†
No 172 98 74 0.18
Yes 11 4 7
SCC: Squamous cell carcinoma; AD: Adenocarcinoma and Adenosquamous
carcinoma; WD: well differentiated; MD: moderately differentiated; PD: poorly
differentiated.
* by the Chi-square test,
† No="past/non smoking” Yes="current smoking”.
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whereas the prognosis of MD tumors without CA12 was
similar to the PD tumors. The prognosis of PD tumors
tended to be also influenced by CA12 expression, but
less than that of MD tumors. The combined category 2
and 3 showed the clear discrimination in disease-free
survival suggesting that CA12 may offer additional dis-
crimination ability in MD and PD tumors.
Why would CA12 expression be associated with a
superior prognosis in our study? According to the litera-
ture, CA12 is expressed in a variety of normal human tis-
sues, including the surface glandular cells of the large
bowel, and fluid-forming areas such as the mesothelium,
the coelomic epithelium of the ovary, the nonpigmented
epithelium of ciliary processes, the distal convoluted
tubule of the kidney, and the choroid plexus of the brain.
All of these tissues have highly specialized functions, pre-
dominantly related to fluid formation and acid-base
balance [1,11,12]. Recently, CA12 was investigated as a
target for glaucoma therapy because CA12 is diffusely
expressed in glaucomatous eyes [12]. Other microarray
studies have shown that CA12 expression is up-regulated
in estrogen-dependent breast cancers [13], and is also
associated with vitamin D-responsive subtypes of colon
cancer cell lines [14], suggesting that CA12 is expressed
in cells with specific functions and in terminally differen-
tiated cells. Gene expression profile in our microarray
analysis shows upregulated estrogen receptor degradation
enhancer gene and estrogen receptor 1 in poorly-differ-
entiated tumors compared with the well-differentiated
tumors, probably explaining increased expression of
CA12 gene in histologically more differentiated type of
breast cancer which shows estrogen-dependent growth.
CA12 also tends to be expressed in the normal tissue
counterparts of several solid tumors [3,15], even though
CA12 is known as one of the tumor-associated carbonic
Figure 2 Microarray analysis. (A) Microarray sample tree of 7 patients and Dendrogram. Average linkage hierarchical clustering of the seven
samples using the entire 54,675 probe sets showed well differentiated (WD) and poorly differentiated (PD) tumors tended to be located more
closely together in each subset. Patient 1 and 2 represent the 2 patients with WD tumor and patient 3~7 represent the 5 patients with PD
tumor. CA12 gene expression was amplified and marked (thick arrow). (B) Examination of CA12 mRNA quantity by real-time PCR. The quantity of
CA12 gene was expressed as a ratio of mean quantity of CA12 to b-actin.
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Figure 3 Survival Distributions(DFS, LRFS)by CA12 expression. Disease-free survival (DFS) (A) and Local recurrence-free survival (B) by CA12
expression. p-values are for log rank test.
Table 2 Univariate and multivariate analyses for disease-free survival (DFS) with clinicopathological prognostic factors
in patients with cervical cancer following radiotherapy
Univariate Multivariate
Clinicopathological factors HR (95% CI) p value* HR (95% CI) p value*
Age (> 40 years vs.≤ 40 years) 0.44(0.24-0.82) 0.01 0.46(0.23-0.93) 0.93
CA12 (Positive vs. Negative) 0.58(0.33-1.03)) 0.06 0.54(0.28-1.05) 0.07
Histologic type (AD vs. SCC) 2.37(1.16-4.89) 0.02 2.14(0.88-5.20) 0.09
Tumor size (1 unit increase) 1.35(1.13-1.63) < 0.01 1.11(0.88-1.40) 0.40
Histological grade (MD vs. WD) 2.14(0.83-5.48) 0.11 2.20(0.75-6.42) 0.15
Histological grade (PD vs. WD) 4.54(1.68-12.34) < 0.01 3.52(1.14-10.86) 0.03
Nodal status (Positive vs. Negative) 3.13 (1.68-5.86) < 0.01 2.17(1.09-4.34) 0.03
FIGO stage (IIIA-IVA vs. I~IIB) 2.96(1.52-5.75) < 0.01 3.16(1.60-6.26) < 0.01
FIGO stage (IVB vs. I~IIB) 8.23(3.96-17.07) < 0.01 5.57(2.28-13.63) < 0.01
SCC: Squamous cell carcinoma; AD: Adenocarcinoma and Adenosquamous carcinoma; WD: well differentiated; MD: moderately differentiated; PD: poorly
differentiated; HR: hazard ratio; CI: confidence interval.
* from the Cox regression analysis.
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Figure 4 Survival Distributions(DFS,LRFS) by histologic grades. Disease-free survival (DFS) (A) and Local recurrence-free survival (B) by
histologic grades. p-values are for log rank test.
Table 3 Univariate and multivariate analyses for local recurrence-free survival (LRFS) with clinicopathological
prognostic factors in patients with cervical cancer following radiotherapy
Univariate Multivariate
Clinicopathological factors HR (95% CI) p value* HR (95% CI) p value*
Age (> 40 years vs.≤ 40 years) 0.44(0.17-1.13) 0.09 0.41(0.14-1.24) 0.12
CA12 (Positive vs. Negative) 0.37(0.136-1.01)) 0.05 0.30(0.09-1.00) 0.05
Histologic type (AD vs. SCC) 3.44(1.26-9.41) 0.02 2.31(0.65-8.19) 0.19
Tumor size (1 unit increase) 1.47(1.12-1.94) 0.01 1.61(1.09-2.36) 0.02
Histologic grade (MD vs. WD) 3.12(0.40-24.42) 0.28 2.37(0.29-19.07) 0.42
Histologic grade (PD vs. WD) 11.56(1.47-90.37) 0.02 7.15(0.85-59.99) 0.07
FIGO stage (IIIA-IVA vs. I~IIB) 3.37(1.35-8.37) 0.01 3.43(1.22-9.61) 0.02
FIGO stage IVB vs. I~IIB) 2.45(0.54-11.09) 0.24 0.75(0.12-4.67) 0.76
SCC: Squamous cell carcinoma; AD: Adenocarcinoma and Adenosquamous carcinoma; WD: well differentiated; MD: moderately differentiated; PD: poorly
differentiated; HR: hazard ratio; CI: confidence interval.
* p-value from the Cox regression.
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Table 4 Univariate and multivariate analyses for disease-free survival (DFS) and local recurrence-free survival (LRFS)
with combined CA12/Differentiation parameters in 173 patients with cervical cancer following radiotherapy
Combined Categories of
CA12 and histologic
differentiation
DFS LRFS
Category Combination HR (95% CI) Univariate
Multivariate*
p value Univariate
Multivariate*
HR (95% CI) Univariate
Multivariate*
p value Univariate
Multivariate*
1(N = 81) CA12(-)/WD, 1 (Ref) 1 (Ref)
CA12(+)/WD,
MD
1 (Ref) 1 (Ref)
2(N = 65) CA12(+)/PD 1.81 (0.96-3.39) 0.07 2.28 (0.76-6.80) 0.14
CA12(-)/MD 1.82 (0.96-3.46) 0.07 3.01 (0.96-9.40) 0.06
3(N = 27) CA12(-)/PD 3.62 (1.76-7.41) < 0.01 5.94 (1.94-18.17) < 0.01
2.82 (1.32-6.04) < 0.01 5.80 (1.61-20.98) < 0.01
Ref: Reference value; HR: hazard ratio; PD: poorly differentiated; MD: moderately differentiated; WD: well differentiated.
*adjusted for age group, FIGO stage, tumor size, and pathological type.
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CA12 expression is associated with less aggressive pheno-
type [3,4,13,16]. As opposed to this, CA12 was reported
to be associated with a poor response to radiotherapy in
two cervical cancer studies [17,18]. The common finding
of the latter two studies was the increased gene expres-
sion of HIF1-a which was observed at the same time
with CA12 overexpression, suggesting that CA12 predicts
a poor prognosis in circumstances where HIF1-a expres-
sion is also elevated. We did not find significant differ-
ence in HIF1-a expression in along with CA12, however,
decrease of hypoxia inducible protein 2 were observed
along with CA12 down regulation in poorly differentiated
tumors. Although the studies of breast cancer [5] and our
previous studies for cervical cancer [3,4] all revealed that
there is no correlation between the expression of CA12
with hypoxia surrogated marker CA9, it is yet to be
determined whether the expression of CA12 in cervical
cancer is predominantly regulated by a differentiation-
related mechanism rather than by tumor hypoxia. Given
that CA12 expression is frequently observed in normal
tissues, and sometimes as well as in tumor tissues of the
same origin, CA12 might be epigenetically silenced dur-
ing the dedifferentiation process of malignant transfor-
mation of epithelial cells. Supporting this speculation is a
report of the stage-specific and transient expression of
CA12 in an early stage of spermatogenesis [19].
Conclusions
In conclusion, CA12 appears to be strongly associated
with the histologic grade of uterine cervical cancers.
CA12 expression has prognostic value when combined
with histologic grade. The combined category system
developed in this study may be applicable as an adjunct
prognostic indicator of survival in patients with uterine
cervical cancer treated with radiotherapy.
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